- Conditions
- Breast Cancer
- Interventions
- pegfilgrastim, AC regimen, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 3,294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2027
- U.S. locations
- 539
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 369 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 5,563
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumococcal Infections
- Interventions
- V114 Lot 1, V114 Lot 2, Prevnar 13™
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 1,051 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 27 more
- Conditions
- Benzodiazepine Refractory Status Epilepticus
- Interventions
- Fosphenytoin, Levetiracetam, Valproic acid
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 65
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 33 more
- Conditions
- Mohs Micrographic Surgery, Excision Margin
- Interventions
- Timolol 0.5% Ophthalmic Solution, Hydrogel of placebo
- Drug · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Sacramento, California
- Conditions
- Covid19
- Interventions
- uEXPLORER/mCT
- Device
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Primary Cutaneous B-Cell Non-Hodgkin Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Alisertib, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 5
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 2 more
- Conditions
- Inhalation Injury
- Interventions
- Standard of Care
- Other
- Lead sponsor
- American Burn Association
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 6 more
- Conditions
- Down Syndrome, ADHD
- Interventions
- Quillivant XR, Placebo
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 4
- States / cities
- Sacramento, California • Boston, Massachusetts • Cincinnati, Ohio + 1 more
- Conditions
- Alpha-1 Antitrypsin Deficiency, AATD
- Interventions
- INBRX-101/rhAAT-Fc
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Sacramento, California • Gainesville, Florida • Miami, Florida + 2 more
- Conditions
- Hepatorenal Syndrome
- Interventions
- Terlipressin, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Relapsing Forms of Multiple Sclerosis
- Interventions
- Fingolimod
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4,125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 34
- States / cities
- Cullman, Alabama • Oceanside, California • Sacramento, California + 30 more
- Conditions
- Aggressive Behavior in Fragile X Syndome
- Interventions
- SRX246, Placebo
- Drug
- Lead sponsor
- Azevan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
- Conditions
- Multiple Sclerosis
- Interventions
- Blood Draw
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Head and Neck Cancer
- Interventions
- Pembrolizumab, Epacadostat, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 14
- States / cities
- Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more
- Conditions
- HIV Infections
- Interventions
- Recombinant human interleukin-7
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 5
- States / cities
- Sacramento, California • Miami, Florida • Chicago, Illinois + 1 more
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- HIV-1 Infection
- Interventions
- FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
- Conditions
- Crohn's Disease
- Interventions
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3, Guselkumab Dose 4, Guselkumab Dose 5, Guselkumab, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 109
- States / cities
- Dothan, Alabama • Mobile, Alabama • Tucson, Arizona + 83 more
- Conditions
- Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
- Interventions
- Nerandomilast
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,666 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 58
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more
- Conditions
- Ovarian Cancer, Primary Peritoneal Carcinoma
- Interventions
- Å6 subcutaneous injection
- Drug
- Lead sponsor
- Ångstrom Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Casa Grande, Arizona • Fresno, California + 21 more
- Conditions
- Multiple Sclerosis
- Interventions
- Fampridine-SR
- Drug
- Lead sponsor
- Acorda Therapeutics
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Fayetteville, Arkansas • Berkeley, California + 33 more
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- melphalan, peripheral blood stem cell transplantation, holmium Ho 166 DOTMP
- Drug · Procedure · Radiation
- Lead sponsor
- Poniard Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Sacramento, California • Nashville, Tennessee + 2 more
- Conditions
- Cervical Cancer, Endometrial Cancer, Gastrointestinal Complications, Perioperative/Postoperative Complications, Radiation Toxicity, Urinary Complications, Urinary Tract Toxicity
- Interventions
- Standard radiation therapy, intensity-modulated radiation therapy
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 289 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 129
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 106 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin degludec/insulin aspart, insulin aspart, insulin detemir
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 362 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 19 more